# Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome

> **NCT00138723** · PHASE3 · COMPLETED · sponsor: **Pfizer**

## Conditions studied

- Overactive Bladder

## Interventions

- **DRUG:** SPM 907

## Key facts

- **NCT ID:** NCT00138723
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2005-02
- **Final completion:** 2005-02
- **Target enrollment:** — (—)
- **Last updated:** 2008-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00138723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00138723, "Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00138723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*